INT284521

From wiki-pain
Revision as of 14:02, 20 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2009
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 13.86
Pain Relevance 1.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CX3CL1) extracellular region (CX3CL1) plasma membrane (CX3CL1)
cytoplasm (CX3CL1)
Anatomy Link Frequency
coronary artery 1
CX3CL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
COX-2 inhibitor 23 99.84 Very High Very High Very High
Inflammation 447 97.08 Very High Very High Very High
Angina 11 96.40 Very High Very High Very High
cytokine 131 90.40 High High
chemokine 174 81.20 Quite High
antagonist 11 30.24 Quite Low
metalloproteinase 102 5.00 Very Low Very Low Very Low
cINOD 4 5.00 Very Low Very Low Very Low
Inflammatory response 2 5.00 Very Low Very Low Very Low
fibrosis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperlipidemia 231 99.98 Very High Very High Very High
Diabetes Mellitus-type I 264 99.56 Very High Very High Very High
Diabetes Mellitus 275 99.54 Very High Very High Very High
Coronary Artery Disease 495 99.28 Very High Very High Very High
Cardiovascular Disease 33 99.28 Very High Very High Very High
INFLAMMATION 440 97.08 Very High Very High Very High
Cv General 3 Under Development 11 96.40 Very High Very High Very High
Atherosclerosis 198 91.48 High High
Herpes Simplex Virus 238 89.44 High High
Infection 104 89.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The reduction in the fractalkine levels in the controls also indicates that the selected measurement time-points were adequate.
Negative_regulation (reduction) of fractalkine
1) Confidence 0.27 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 0.68 Pain Relevance 0.22
0.0008) by administering fractalkine antibodies.19 These studies identified a critical role for fractalkine in the pathogenesis of acute rejection and suggest that fractalkine inhibition might be a potential therapeutic target.
Negative_regulation (inhibition) of fractalkine
2) Confidence 0.27 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 0.56 Pain Relevance 0.21
However, postprandial fractalkine levels in control subjects were reduced, a finding paralleled by in vitro cell culture data.
Negative_regulation (reduced) of fractalkine
3) Confidence 0.27 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.39 Pain Relevance 0.15
Previous studies reported that soluble fractalkine was increased in CHD patients as compared to controls, and that membrane-bound fractalkine was increased in human carotid arteries and in animal models.37,38 In another study serum fractalkine levels were determined:22 These data showed that patients with unstable angina (1,199 ± 112 pg/mL) had enhanced fractalkine levels as compared with control levels (423 ± 25 pg/mL) and that six-month atorvastatin therapy, but not simvastatin therapy, greatly reduced the fractalkine levels in the investigated patients (587 ± 89 pg/mL).
Spec (investigated) Negative_regulation (reduced) of fractalkine associated with angina and coronary artery disease
4) Confidence 0.27 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 0.95 Pain Relevance 0.12
Postprandial hyperlipemia significantly reduced fractalkine levels in the controls, whereas it had no effect in the patients.
Negative_regulation (reduced) of fractalkine associated with hyperlipidemia
5) Confidence 0.27 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 0.88 Pain Relevance 0.18
In vitro, lipofundin used as a hyperlipemic stimulus was added to vessel wall cells and reduced fractalkine levels.
Negative_regulation (reduced) of fractalkine
6) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2762434 Disease Relevance 1.42 Pain Relevance 0.13
Indeed, fractalkine levels were reduced in patients with coronary artery disease after a six-week statin treatment.22 Thus, rehabilitation may normalize levels of fractalkine.
Negative_regulation (reduced) of fractalkine in coronary artery associated with cardiovascular disease
7) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.33 Pain Relevance 0.15
Postprandial hyperlipemia reduced the fractalkine levels in control subjects and in vessel wall cells in vitro, whereas postprandial hyperlipemia did not result in significantly different fractalkine levels in diabetic and CHF patients according to ANOVA.
Negative_regulation (reduced) of fractalkine associated with diabetes mellitus and hyperlipidemia
8) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.51 Pain Relevance 0.15
However, we did not find any significant alterations in CHD and diabetic patients, whereas the fractalkine levels in controls were reduced.
Negative_regulation (reduced) of fractalkine associated with coronary artery disease and diabetes mellitus
9) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2762434 Disease Relevance 1.52 Pain Relevance 0.14
Taken together, the data indicate that the fractalkine levels were only reduced in control subjects, whereas in CHD the levels remained low and in IDDM patients the levels fluctuated, although the differences were not significant according to ANOVA.
Negative_regulation (reduced) of fractalkine associated with diabetes mellitus-type i and coronary artery disease
10) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.09 Pain Relevance 0.03
Postprandial hyperlipemia does not reduce fractalkine levels in IDDM and CHD patients
Neg (not) Negative_regulation (reduce) of fractalkine associated with diabetes mellitus-type i, coronary artery disease and hyperlipidemia
11) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.88 Pain Relevance 0.12
9), Flt3-ligand, Fractalkine, IGFBPs and Osteoprotegerin were strongly inhibited by COX-2 inhibitor pretreatment demonstrating the specificity of downstream pathways regulated via COX-2 and NF-kB.
Negative_regulation (inhibited) of Fractalkine associated with cox-2 inhibitor
12) Confidence 0.04 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 0.65 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox